Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.

OBJECTIVE Lansoprazole and tacrolimus are substrates of ATP binding cassette (ABC) transporters such as P-glycoprotein (ABCBI/multidrug resistance 1) and cytochrome P450 (CYP). The purpose of this study was to investigate the implication of the ABCB1 C3435Tpolymorphism on the pharmacokinetics of (R)-lansoprazole, the major enantiomer, in CYP2C19 extensive metabolizers (EMs) and on gastroesophageal symptoms in renal transplant recipients receiving tacrolimus. MATERIALS 24 recipients who were CYP2C19 EMs were studied. METHODS Oral administration of 30 mg lansoprazole was started 2 days before transplantation. On Day 2 before and Day 28 after transplantation, the plasma concentrations of (R)-lansoprazole and tacrolimus were measured. RESULTS Pretransplantation, there were no significant differences in the pharmacokinetic parameters of (R)-lansoprazole between the 3 ABCBI C3435T genotypes. However, after renal transplantation, the peak plasma concentration (Cma ) and area under the plasma concentration-time curve (AUCO-24) of (R)-lansoprazole in patients with the ABCB1 C3435T C allele significantly increased, but not in patients with the TT genotype. These pharmacokinetic variations in (R)-lansoprazole did not influence the AUC of tacrolimus. There were no significant differences in the frequency of gastroesophageal symptoms among the three ABCB] C3435Tgenotypes. CONCLUSIONS (R)-lansoprazole concentrations significantly increased in CYP2C19 extensive metabolizers with the ABCB1 C3435T C allele, but not TT genotype, after renal transplantation. However, the clinical relevance of this observation may be minor because these pharmacogenetic changes were not associated with the occurrence of gastroesophageal complications.

[1]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  F. Leblond,et al.  Drug metabolism in chronic renal failure. , 2003, Current drug metabolism.

[3]  T. Suzuki,et al.  A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.

[4]  O. Ogawa,et al.  Lansoprazole—Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism , 2004, The Annals of pharmacotherapy.

[5]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[6]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[7]  M. Miura,et al.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.

[8]  J. Balian,et al.  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.

[9]  Yoshinori Morita,et al.  MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.

[10]  M. Homma,et al.  Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. , 2002, Transplantation proceedings.

[11]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[12]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[13]  Ji-Young Park,et al.  Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 , 2002, Clinical pharmacology and therapeutics.

[14]  H. Ackermann,et al.  ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. , 2005, Journal of the American Society of Nephrology : JASN.

[15]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[16]  C. Nakamura,et al.  Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.

[17]  N. Ohkohchi,et al.  Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations , 2004, The Journal of pharmacy and pharmacology.

[18]  T. Habuchi,et al.  Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  J. Goldstein,et al.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. , 1997, Pharmacogenetics.

[20]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[21]  Tetsuro Kato,et al.  Chronopharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Occurrence of Acute Rejection , 2003, Journal of clinical pharmacology.

[22]  D. Dunn,et al.  Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.

[23]  T. Andersson.  Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors , 1996, Clinical pharmacokinetics.

[24]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[25]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[26]  T. Uno,et al.  Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes , 2004, Journal of clinical pharmacology.

[27]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[28]  R. Komorowski,et al.  Gastrointestinal complications in renal transplant recipients. , 1986, American journal of clinical pathology.

[29]  J. Chun,et al.  Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[30]  M. Fromm,et al.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.